Overview

Randomized Phase III Adjuvant Study for Stage III Colorectal Cancer

Status:
Unknown status
Trial end date:
2012-12-01
Target enrollment:
Participant gender:
Summary
A randomized controlled study is conducted on patients with histological stage III colorectal cancer assigned to postoperative adjuvant therapy of uracil-tegafur plus leucovorin (UFT+LV), UFT+LV / UFT, or UFT+LV+PSK / UFT+PSK. The usefulness of the three regimens was evaluated by comparing the disease-free survival rate, overall survival rate, incidence and severity of adverse event, and quality of life.
Phase:
Phase 3
Details
Lead Sponsor:
Hokkaido Gastrointestinal Cancer Study Group
Collaborator:
Hokkaido University Hospital
Treatments:
Krestin
Leucovorin
Levoleucovorin
polysaccharide-K
Tegafur